Clinical Scorecard: Worldwide Incidence of Long COVID, Its Variants, and Associated Risk Factors: A Comprehensive Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Long COVID (postacute sequelae of COVID-19)
Key Mechanisms
Multisystemic syndrome with diverse subtypes including respiratory, fatigue, psychological, and neurological symptoms persisting after SARS-CoV-2 infection
Target Population
Individuals with confirmed SARS-CoV-2 infection
Care Setting
Global, including outpatient and follow-up clinical settings
Key Highlights
Global pooled prevalence of long COVID is 36% (95% CI, 33%–40%) based on 144 studies.
Most prevalent long COVID subtypes: respiratory (20%), general fatigue (20%), psychological (18%), neurological (16%).
Strongest risk factors: unvaccinated status (OR 2.09), infection with pre-Omicron variants (OR 1.74), and female sex (OR 1.56).
Guideline-Based Recommendations
Diagnosis
Define long COVID as presence of ≥1 new or persistent symptom ≥2 months after SARS-CoV-2 infection.
Use consistent symptom assessment and follow-up timing for diagnosis.
Management
Recognize long COVID as a multisystem condition requiring multidisciplinary care.
Consider vaccination to reduce risk of long COVID.
Monitoring & Follow-up
Follow patients longitudinally for at least 1–2 years to assess symptom persistence and subtype evolution.
Monitor common symptoms including respiratory, fatigue, psychological, and neurological manifestations.
Risks
Identify unvaccinated individuals, females, and those infected with pre-Omicron variants as higher risk groups.
Consider regional prevalence differences, with highest rates reported in South America.
Patient & Prescribing Data
COVID-19 survivors globally, including diverse geographic regions and variant exposures
Vaccination is associated with reduced odds of developing long COVID; ongoing surveillance and supportive care remain essential.
Clinical Best Practices
Use standardized definitions and consistent follow-up intervals (≥2 months) for long COVID assessment.
Incorporate evaluation of multiple symptom subtypes to capture the heterogeneity of long COVID.
Prioritize vaccination campaigns to mitigate long COVID risk.
Design follow-up studies with global representation and uniform measures to improve understanding and management.
